Published 2023 | Version v1
Poster Open

Targeting Drug Resistance in Colorectal Cancer: A Drug Repurposing Approach to Overcome FOLFOX Resistance

Authors/Creators

  • 1. Precision Medicine Lab (CECOS RMI)
  • 2. Rehman Medical College
  • 3. Khyber Medical College
  • 4. Institute of Integrative Biosciences, CECOS University
  • 5. Department of Bioengineering, University of Engineering and Applied Sciences, Swat, Pakistan
  • 6. Centre for Genomic Sciences, Rehman Medical Institute Peshawar, Pakistan

Description

Colorectal cancer (CRC) is the third most prevalent and second most fatal cancer worldwide [1]. Despite treatment advancements, the five-year survival rate remains low [2]. FOLFOX, the first-line treatment for advanced CRC, is a common chemotherapy regimen used in clinics [3]. However, treatment often fails due to acquired resistance, observed in 90% of metastatic patients [2]. Therefore, a more efficient and cost-effective drug repurposing approach is needed.

 

Files

Safoora Zia 2023.pdf

Files (745.3 kB)

Name Size Download all
md5:517d3044a7e99d2f330d31abd417be90
745.3 kB Preview Download

Additional details

References

  • 1. Sung, H., et al. (2021). "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries," CA: A Cancer Journal for Clinicians.
  • 2. Esin, E., & Yalcin, S. (2016). "Maintenance strategy in metastatic colorectal cancer: A systematic review," Cancer Treatment Reviews.
  • 3. Benson, A. B., et al. (2021). "Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology," J Natl Compr Canc Netw.